Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience
2019
ABSTRACTOBJECTIVESIndolent B-cell non-Hodgkin lymphomas (iNHLs) are considered incurable.
Rituximabmaintenance and
yttrium-90
ibritumomab tiuxetan(90Y-IT) consolidation are promising post-remissi...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
28
References
0
Citations
NaN
KQI